These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 32517418)

  • 1. Comparison of Amyloid Positivity Rate and Accumulation Pattern between Amnestic and Non-Amnestic Type Mild Cognitive Impairment.
    Lee SH; Lee JH; Byun MS; Yi D; Jung G; Park JE; Lee DY
    Psychiatry Investig; 2020 Jun; 17(6):603-607. PubMed ID: 32517418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain metabolism and cerebrospinal fluid biomarkers profile of non-amnestic mild cognitive impairment in comparison to amnestic mild cognitive impairment and normal older subjects.
    Coutinho AM; Porto FH; Duran FL; Prando S; Ono CR; Feitosa EA; Spíndola L; de Oliveira MO; do Vale PH; Gomes HR; Nitrini R; Brucki SM; Buchpiguel CA
    Alzheimers Res Ther; 2015 Sep; 7(1):58. PubMed ID: 26373380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Association of β-Amyloid with Cognition and Striatal Dopamine in Early, Non-Demented Parkinson's Disease.
    Oh YS; Yoo SW; Lyoo CH; Yoo JY; Yoon H; Ha S; Lee KS; Kim JS
    J Parkinsons Dis; 2021; 11(2):605-613. PubMed ID: 33646180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential and subtype-specific neuroimaging abnormalities in amnestic and nonamnestic mild cognitive impairment: A systematic review and meta-analysis.
    Yeung MK; Chau AK; Chiu JY; Shek JT; Leung JP; Wong TC
    Ageing Res Rev; 2022 Sep; 80():101675. PubMed ID: 35724862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effect of Clinical Characteristics and Subtypes on Amyloid Positivity in Patients with Amnestic Mild Cognitive Impairment.
    Kim JY; Lim JH; Jeong YJ; Kang DY; Park KW
    Dement Neurocogn Disord; 2019 Dec; 18(4):130-137. PubMed ID: 31942172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beta-amyloid deposition and cognitive function in patients with major depressive disorder with different subtypes of mild cognitive impairment: (18)F-florbetapir (AV-45/Amyvid) PET study.
    Wu KY; Liu CY; Chen CS; Chen CH; Hsiao IT; Hsieh CJ; Lee CP; Yen TC; Lin KJ
    Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1067-76. PubMed ID: 26739329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential patterns of regional cerebral hypometabolism according to the level of cerebral amyloid deposition in patients with amnestic mild cognitive impairment.
    Jeon SY; Yi D; Byun MS; Choi HJ; Kim HJ; Lee JH; Baek H; Choe YM; Lee Y; Woo JI; Lee DY
    Neurosci Lett; 2016 Oct; 632():104-8. PubMed ID: 27574728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and Outcomes of Amyloid Positivity Among Persons Without Dementia in a Longitudinal, Population-Based Setting.
    Roberts RO; Aakre JA; Kremers WK; Vassilaki M; Knopman DS; Mielke MM; Alhurani R; Geda YE; Machulda MM; Coloma P; Schauble B; Lowe VJ; Jack CR; Petersen RC
    JAMA Neurol; 2018 Aug; 75(8):970-979. PubMed ID: 29710225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI.
    Vos SJ; van Rossum IA; Verhey F; Knol DL; Soininen H; Wahlund LO; Hampel H; Tsolaki M; Minthon L; Frisoni GB; Froelich L; Nobili F; van der Flier W; Blennow K; Wolz R; Scheltens P; Visser PJ
    Neurology; 2013 Mar; 80(12):1124-32. PubMed ID: 23446677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Differentiation of Amnestic Type MCI from the Non-Amnestic Types by Structural MRI.
    Csukly G; Sirály E; Fodor Z; Horváth A; Salacz P; Hidasi Z; Csibri É; Rudas G; Szabó Á
    Front Aging Neurosci; 2016; 8():52. PubMed ID: 27065855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Learning potential and visuospatial memory could predict amyloid-beta positron emission tomography positivity in amnestic mild cognitive impairment.
    Shin MG; Lee YM; Kim YJ; Lee H; Pak K; Choi KU
    Psychiatry Res Neuroimaging; 2023 Oct; 335():111705. PubMed ID: 37659242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of subthreshold levels of amyloid deposition on conversion to dementia in patients with amyloid-negative amnestic mild cognitive impairment.
    Kim HJ; Oh JS; Lim JS; Lee S; Jo S; Chung EN; Shim WH; Oh M; Kim JS; Roh JH; Lee JH;
    Alzheimers Res Ther; 2022 Jul; 14(1):93. PubMed ID: 35821150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical relevance of amnestic versus non-amnestic mild cognitive impairment subtyping in Parkinson's disease.
    Chung SJ; Park YH; Yun HJ; Kwon H; Yoo HS; Sohn YH; Lee JM; Lee PH
    Eur J Neurol; 2019 May; 26(5):766-773. PubMed ID: 30565368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olfactory identification in amnestic and non-amnestic mild cognitive impairment and its neuropsychological correlates.
    Vyhnalek M; Magerova H; Andel R; Nikolai T; Kadlecova A; Laczo J; Hort J
    J Neurol Sci; 2015 Feb; 349(1-2):179-84. PubMed ID: 25614440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Nomogram for Predicting Amyloid PET Positivity in Amnestic Mild Cognitive Impairment.
    Kim SE; Woo S; Kim SW; Chin J; Kim HJ; Lee BI; Park J; Park KW; Kang DY; Noh Y; Ye BS; Yoo HS; Lee JS; Kim Y; Kim SJ; Cho SH; Na DL; Lockhart SN; Jang H; Seo SW
    J Alzheimers Dis; 2018; 66(2):681-691. PubMed ID: 30320571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuropathological comparisons of amnestic and nonamnestic mild cognitive impairment.
    Dugger BN; Davis K; Malek-Ahmadi M; Hentz JG; Sandhu S; Beach TG; Adler CH; Caselli RJ; Johnson TA; Serrano GE; Shill HA; Belden C; Driver-Dunckley E; Caviness JN; Sue LI; Jacobson S; Powell J; Sabbagh MN
    BMC Neurol; 2015 Aug; 15():146. PubMed ID: 26289075
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Chun MY; Lee J; Jeong JH; Roh JH; Oh SJ; Oh M; Oh JS; Kim JS; Moon SH; Woo SY; Kim YJ; Choe YS; Kim HJ; Na DL; Jang H; Seo SW
    Yonsei Med J; 2022 Mar; 63(3):259-264. PubMed ID: 35184428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal cognitive decline in mild cognitive impairment subjects with early amyloid-β neocortical deposition.
    Ciarmiello A; Giovannini E; Riondato M; Giovacchini G; Duce V; Ferrando O; De Biasi M; Passera C; Carabelli E; Mannironi A; Mansi L; Tartaglione A
    Eur J Nucl Med Mol Imaging; 2019 Sep; 46(10):2090-2098. PubMed ID: 31264171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct Neural Correlates of Executive Function by Amyloid Positivity and Associations with Clinical Progression in Mild Cognitive Impairment.
    Yoon HJ; Kim SG; Kim SH; Choo ILH; Park SH; Seo EH;
    Yonsei Med J; 2019 Oct; 60(10):935-943. PubMed ID: 31538428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [¹⁸F]THK5351 PET Imaging in Patients with Mild Cognitive Impairment.
    Jeong HJ; Lee H; Lee SY; Seo S; Park KH; Lee YB; Shin DJ; Kang JM; Yeon BK; Kang SG; Cho J; Seong JK; Okamura N; Villemagne VL; Na DL; Noh Y
    J Clin Neurol; 2020 Apr; 16(2):202-214. PubMed ID: 32319236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.